Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

20182,498 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 19, Issue 7, pp. 940-952

Field-Weighted Citation Impact: 150.40